Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABCZF OTCMKTS:GNFTF NASDAQ:SXTPW OTCMKTS:TRSBF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZFAbcamC$22.25C$22.25C$5.00▼C$23.80N/AN/A2,659 shsN/AGNFTFGenfit$15.95$10.61$4.14▼$15.95N/AN/A437 shsN/ASXTPW60 Degrees Pharmaceuticals$0.03+13.8%$0.03$0.02▼$0.16N/AN/A10,869 shs100 shsTRSBF3SBio$2.15$2.27$2.00▼$4.74N/AN/A2,351 shsN/AThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZFAbcam0.00%0.00%0.00%0.00%0.00%GNFTFGenfit0.00%+48.37%+48.37%+44.34%+386.27%SXTPW60 Degrees Pharmaceuticals0.00%+5.52%+0.99%-24.63%-64.62%TRSBF3SBio0.00%0.00%-2.27%-23.89%-42.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZFAbcamC$22.25C$22.25C$5.00▼C$23.80N/AN/A2,659 shsN/AGNFTFGenfit$15.95$10.61$4.14▼$15.95N/AN/A437 shsN/ASXTPW60 Degrees Pharmaceuticals$0.03+13.8%$0.03$0.02▼$0.16N/AN/A10,869 shs100 shsTRSBF3SBio$2.15$2.27$2.00▼$4.74N/AN/A2,351 shsN/AThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZFAbcam0.00%0.00%0.00%0.00%0.00%GNFTFGenfit0.00%+48.37%+48.37%+44.34%+386.27%SXTPW60 Degrees Pharmaceuticals0.00%+5.52%+0.99%-24.63%-64.62%TRSBF3SBio0.00%0.00%-2.27%-23.89%-42.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCZFAbcam 0.00N/AN/AN/AGNFTFGenfit 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ATRSBF3SBio 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCZFAbcamN/AN/AN/AN/AN/AN/AGNFTFGenfitN/AN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/AN/ATRSBF3SBioN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCZFAbcamN/AC$0.17130.73N/AN/AN/AN/AN/AN/AGNFTFGenfitN/A-$0.67N/AN/AN/AN/AN/AN/A9/29/2026 (Estimated)SXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ATRSBF3SBioN/AN/AN/AN/AN/AN/AN/AN/A8/26/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABCZFAbcamC$0.070.32%N/A42.48%N/AGNFTFGenfitN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ATRSBF3SBioN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCZFAbcam43.58%GNFTFGenfit11.11%SXTPW60 Degrees PharmaceuticalsN/ATRSBF3SBioN/AInsider OwnershipCompanyInsider OwnershipABCZFAbcamN/AGNFTFGenfitN/ASXTPW60 Degrees PharmaceuticalsN/ATRSBF3SBioN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCZFAbcam1,750N/AN/ANot OptionableGNFTFGenfit159N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableTRSBF3SBio5,411N/AN/ANot OptionableGNFTF, TRSBF, SXTPW, and ABCZF HeadlinesRecent News About These Companies3SBio Inc. (OTCMKTS:TRSBF) Sees Significant Growth in Short InterestJuly 15, 2026 | americanbankingnews.com3SBio Sets June 2026 AGM to Approve Dividend, New Auditor and Share Issue MandateJune 3, 2026 | tipranks.com3SBio Calls Extraordinary Meeting to Approve Mandi Spin-Off DividendApril 1, 2026 | tipranks.com3SBio Proposes HKD 0.25 Final Dividend for 2025 Financial YearMarch 30, 2026 | tipranks.comChinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- UpdateMay 20, 2025 | marketwatch.comBiotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With PfizerMay 20, 2025 | marketwatch.comPfizer Licenses 3SBio Cancer Drug for Record $1.2 BillionMay 20, 2025 | msn.comCosmo and 3SBio Announce Signing of License Agreement for Winlevi® in ChinaJuly 28, 2022 | markets.businessinsider.com3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical developmentAugust 26, 2021 | finance.yahoo.comMedia Sentiment Over TimeGNFTF, TRSBF, SXTPW, and ABCZF Company DescriptionsAbcam OTCMKTS:ABCZFC$22.25 0.00 (0.00%) As of 07/24/2026Abcam Limited, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. Abcam Limited was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam Limited operates as a subsidiary of Danaher Corporation.Genfit OTCMKTS:GNFTF$15.95 0.00 (0.00%) As of 07/24/2026Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.03 +0.00 (+13.75%) As of 07/24/2026 03:51 PM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.3SBio OTCMKTS:TRSBF$2.15 0.00 (0.00%) As of 07/24/20263SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
